Dr Adam Ritchie
Contact information
01865 617623
Old Road Campus Research Build (ORCRB), Roosevelt Drive, Oxford OX3 7DQ
Research groups
Adam Ritchie
BSc, PhD, FHEA
Senior Vaccinologist
Douglas Group
Adam is a Senior Vaccinologist at the Jenner Institute. He is currently focused on the rabies, EBV and COVID-19 vaccine projects, alongside work on policy and regulation as part of Vax-Hub Global. Adam's interest is on translation of academic research into real world impact through the efficient development, manufacture, and clinical testing of vaccine candidates.
Adam works includes the design and delivery of early phase clinical trials, regulatory affairs, public policy, and vaccine manufacturing.
Adam is also a Lecturer in Human Science at St Catherine's College.
Key publications
-
Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs.
Journal article
Joe CCD. et al, (2022), Biotechnology and bioengineering, 119, 48 - 58
-
Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components
Journal article
Fedosyuk S. et al, (2019), Vaccine, 37, 6951 - 6961
-
Making THE vaccine
Journal article
Joe CCD. and Ritchie AJ., (2021), Biochemist, 43, 8 - 13
-
Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation.
Journal article
Dulal P. et al, (2021), Scientific reports, 11
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Journal article
Folegatti PM. et al, (2020), The Lancet, 396, 467 - 478
-
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Journal article
Barrett JR. et al, (2021), Nature Medicine, 27, 279 - 288
-
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Journal article
Ewer KJ. et al, (2021), Nature Medicine, 27, 270 - 278
-
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Journal article
Ramasamy MN. et al, (2020), The Lancet, 396, 1979 - 1993
-
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Journal article
Voysey M. et al, (2021), The Lancet, 397, 99 - 111
-
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
Journal article
Voysey M. et al, (2021), The Lancet, 397, 881 - 891
-
Recombination-mediated escape from primary CD8+ T cells in acute HIV-1 infection
Journal article
Ritchie AJ. et al, (2014), Retrovirology, 11
-
Vertical T cell immunodominance and epitope entropy determine HIV-1 escape
Journal article
Liu MKP. et al, (2012), Journal of Clinical Investigation
-
Quantitative and Qualitative Differences in the T Cell Response to HIV in Uninfected Ugandans Exposed or Unexposed to HIV-Infected Partners
Journal article
Pala P. et al, (2013), Journal of Virology, 87, 9053 - 9063
-
Characterisation of HIV-1 specific T-cell responses in exposed uninfected individuals from a London cohort
Journal article
Ritchie AJ. et al, (2009), RETROVIROLOGY, 6
-
Normal prion protein is expressed on exosomes isolated from human plasma
Journal article
Ritchie AJ. et al, (2013), British Journal of Haematology, 163, 678 - 680
-
Modification of In Vivo and In Vitro T- and B-Cell-Mediated Immune Responses by the Pseudomonas aeruginosa Quorum-Sensing Molecule N-(3-Oxododecanoyl)-l-Homoserine Lactone
Journal article
Ritchie AJ. et al, (2003), Infection and Immunity, 71, 4421 - 4431
Recent publications
-
Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs.
Journal article
Joe CCD. et al, (2022), Biotechnology and bioengineering, 119, 48 - 58
-
Publisher Correction: Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation.
Journal article
Dulal P. et al, (2021), Scientific reports, 11
-
Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation.
Journal article
Dulal P. et al, (2021), Scientific reports, 11
-
Making THE vaccine
Journal article
Joe CCD. and Ritchie AJ., (2021), Biochemist, 43, 8 - 13
-
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Journal article
Barrett JR. et al, (2021), Nature Medicine, 27, 1113 - 1113